ProCE Banner Activity

Real-world Prevalence and Impact of DOR-Related Resistance Mutations Among NNRTI-Naive and Experienced Persons Living With HIV

Conference Coverage
Slideset

In this large retrospective analysis from the British Columbia Centre for Excellence in HIV/AIDS, virologic failure and emergent resistance to DOR were uncommon in both NNRTI-naive and experienced people living with HIV.

Released: October 23, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare